Clinical Trials Logo
  1. Home
  2. Hypotrichosis
  3. NCT05790941

Proof of Concept Study of Latanoprost/Minoxidil (ANR-001.1) Topical Formulation

Hypotrichosis Clinical Trial

Official title:
Proof of Concept of Latanoprost/Minoxidil (ANR-001.1) Topical Formulation for Eyebrows

Clinical Trial Summary

Study to Evaluate the safety and efficacy of a Latanoprost/Minoxidil formulation vs. placebo for the treatment of hypotrichosis of the eyebrows.

Clinical Trial Description

A Single-Blind placebo controlled trial of the efficacy and safety of the treatment of hypotrichosis of the eyebrows comparing a subset of patients receiving a combination of latanoprost/minoxidil formulation as compared to placebo measured by a validated imaging system. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05790941
Study type Interventional
Source Aneira Pharma, Inc.
Contact Dan Cosgrove, M.D.
Phone 760-777-7698
Email heidi@wellmax.com
Status Recruiting
Phase Early Phase 1
Start date March 11, 2023
Completion date June 30, 2023
View Details
See also
  Status Clinical Trial Phase
Completed NCT01448525 - Study Assessing Patient Satisfaction With LATISSE® for Increasing Eyelash Prominence Phase 4
Completed NCT00958035 - Study of Bimatoprost Solution in Increasing Eyelash Prominence in African Americans With Eyelash Hypotrichosis Phase 4
Completed NCT01891487 - Safety and Efficacy of Bimatoprost 0.03% Solution for the Treatment of Thinning Eyebrows Phase 4
Completed NCT01387906 - Latisse (Bimatoprost .03% Opthalmic Solution) for the Treatment of Hypotrichosis of the Eyebrows: Latisse Versus Placebo Phase 4
Recruiting NCT05723198 - A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata Phase 3
Completed NCT01200251 - Study of Bimatoprost Gel on Eyelash Growth Phase 3
Completed NCT00907426 - Safety and Efficacy Study of Bimatoprost to Treat Hypotrichosis of the Eyelashes After Application to the Eyelid Margin Phase 3